Anti-restenosis stent coatings to be developed:
This article was originally published in Clinica
Executive Summary
CV Therapeutics is to develop drug-containing polymer coatings for cardiology stents with the aim of cutting restenosis rates. CVT has developed a group of small molecule cell inhibitors, including its lead compound CVT-313, which the US company believes may treat the cell proliferation that causes cleared arteries to re-close.